Zacks Research Issues Positive Outlook for Exelixis Earnings

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Stock analysts at Zacks Research upped their Q2 2025 earnings per share estimates for Exelixis in a research note issued to investors on Tuesday, June 3rd. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of $0.52 per share for the quarter, up from their previous forecast of $0.48. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q3 2025 earnings at $0.55 EPS, Q4 2025 earnings at $0.57 EPS, FY2025 earnings at $2.19 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.75 EPS, FY2026 earnings at $2.51 EPS, Q1 2027 earnings at $0.66 EPS and FY2027 earnings at $2.89 EPS.

Several other equities research analysts also recently commented on the company. Stifel Nicolaus boosted their target price on Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a report on Wednesday, May 14th. Stephens reissued an "equal weight" rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 target price on shares of Exelixis in a report on Wednesday, May 14th. Piper Sandler boosted their target price on Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Finally, Citigroup boosted their target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, Exelixis presently has an average rating of "Moderate Buy" and a consensus price target of $39.35.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded up $0.66 during mid-day trading on Friday, hitting $43.03. 2,336,895 shares of the stock traded hands, compared to its average volume of 2,334,819. Exelixis has a 52 week low of $21.36 and a 52 week high of $48.85. The company has a market cap of $11.73 billion, a price-to-earnings ratio of 24.31, a PEG ratio of 1.13 and a beta of 0.28. The stock has a fifty day moving average price of $39.03 and a 200-day moving average price of $36.64.

Hedge Funds Weigh In On Exelixis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Tallon Kerry Patrick bought a new stake in shares of Exelixis during the 4th quarter worth approximately $2,619,000. Janney Montgomery Scott LLC raised its position in shares of Exelixis by 9.5% in the 4th quarter. Janney Montgomery Scott LLC now owns 33,296 shares of the biotechnology company's stock worth $1,109,000 after acquiring an additional 2,897 shares in the last quarter. Spire Wealth Management raised its position in shares of Exelixis by 49.9% in the 4th quarter. Spire Wealth Management now owns 9,010 shares of the biotechnology company's stock worth $300,000 after acquiring an additional 3,000 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Exelixis in the 4th quarter worth $7,455,000. Finally, Entropy Technologies LP grew its stake in Exelixis by 18.7% during the 4th quarter. Entropy Technologies LP now owns 21,731 shares of the biotechnology company's stock worth $724,000 after buying an additional 3,431 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Insiders Place Their Bets

In other news, EVP Patrick J. Haley sold 126,383 shares of Exelixis stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $47.96, for a total value of $6,061,328.68. Following the completion of the transaction, the executive vice president now owns 446,459 shares in the company, valued at approximately $21,412,173.64. The trade was a 22.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $45.47, for a total value of $3,309,124.72. Following the completion of the transaction, the chief marketing officer now owns 465,393 shares of the company's stock, valued at approximately $21,161,419.71. This trade represents a 13.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock worth $21,024,817 over the last quarter. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.